Follow‐up is not justified in patients with typical lung carcinoids without lymph node involvement treated with curative intent: A Danish Multi‐ENETS Center of Excellence Study
Open Access
- 19 March 2026
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (3) , e70164
Abstract
Typical carcinoids (TC) are neuroendocrine malignancies of the lung with low risk of recurrence and a favorable prognosis. It is unclear whether lymph node status and tumor size affect the recurrence risk. Following radical surgery, current guidelines recommend comprehensive follow‐up including regular computed tomography (CT) imaging. We aimed to estimate the risk of recurrence in curatively treated patients with TC and to discuss the justification of the current comprehensive follow‐up program. We identified all patients diagnosed with TC from 2009 to 2020 at Aarhus University Hospital, Denmark and Copenhagen University Hospital, Rigshospitalet, Denmark. Patients without distant metastases (M0) who underwent radical surgery (R0) were included in the analysis. The risk of recurrence was estimated using the Aalen‐Johansen method treating death as a competing risk. Fine‐Gray models were used to evaluate the effect of lymph node status and tumor size. Three‐hundred and thirty patients were included in the analysis, of whom 40 had lymph node involvement and 290 did not. During a total follow‐up time of 2806 years across all patients, with an individual median of 8.1 years (IQR: 5.9–11.2), 10 patients had recurrence: four in the node‐negative group and six in the node‐positive group. The 10‐year cumulative risk of recurrence for all patients was 3.4% (95% confidence interval (CI): 1.7–6.0), for patients without lymph node involvement 1.6% (95% CI: 0.5–3.8), and for patients with lymph node involvement 15.6% (95% CI: 6.3–28.8). Of the four recurrences in the node‐negative group, one led to re‐resection with curative intent. Patients with TC without lymph node involvement have a very low risk of recurrence. Thus, we recommend tailoring the follow‐up program based on lymph node status, with node‐negative patients being excluded from regular follow‐up programs.Keywords
This publication has 18 references indexed in Scilit:
- Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus GuidelinesJournal of Thoracic Oncology, 2020
- Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of ExcellenceLung Cancer, 2019
- Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study—The Importance of Pathological N Status, More Than We ThoughtLung, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Predictors of Disease-free Survival and Recurrence in Patients with Resected Bronchial Carcinoid TumorsThe Thoracic and Cardiovascular Surgeon, 2015
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsAnnals of Oncology, 2015
- Recurrence of Pulmonary Carcinoid Tumors After Resection: Implications for Postoperative SurveillanceThe Annals of Thoracic Surgery, 2013
- Outcome and Prognostic Factors in Bronchial Carcinoids: A Single-Center ExperienceJournal of Thoracic Oncology, 2013
- Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillanceThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Complete resection in lung cancer surgery: proposed definitionLung Cancer, 2005